Catalyst Pharmaceutical Research

Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company dedicated to developing and commercializing first-in-class medicines for rare neurological and neuromuscular diseases. The company's lead product, Firdapse (amifampridine), is the first and only approved treatment in the U.S. for Lambert-Eaton myasthenic syndrome (LEMS) in both adults and children. Catalyst has significantly expanded its commercial portfolio through strategic acquisitions, including the anti-epileptic drug Fycompa and the novel dissociative corticosteroid Agamree for Duchenne muscular dystrophy. The company focuses on addressing the unmet needs of patient populations with orphan diseases through a combination of internal development and external asset acquisition. Headquartered in Coral Gables, Florida, Catalyst continues to evaluate new opportunities to grow its footprint in the rare disease space.